deltatrials
Completed PHASE3 NCT00169585

Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)

A National, Multicentric, Randomised, Controlled Trial. Applications of a Critical Pathway Using Levofloxacin for the Management of Patients With Abnormal PSA.

Sponsor: GlaxoSmithKline

Conditions Prostatic Hyperplasia Prostatitis
Interventions Levofloxacin oral tablets
Updated 6 times since 2017 Last updated: May 24, 2017 Started: Mar 31, 2005 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

A PHASE3 clinical study on Prostatic Hyperplasia and Prostatitis, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Avellino, Italy, Bagno A Ripoli (FI), Italy, Bari, Italy, Bologna, Italy, Catania, Italy, Foggia, Italy, Lanzo Torinese (TO), Italy, Lecco, Italy, Matera, Italy, Messina, Italy and 6 more location s